Loading
companiesCompany
Can-Fite BioPharma
Can-Fite is an Israeli company developing adenosine A3 receptor agonists; namodenoson is in phase 3 as a second-line treatment for liver cancer in patients with poor liver function.
Also called: Can-Fite BioPharma LtdCan Fite Biopharma
Overview
Can-Fite BioPharma, founded in 1994 and based in Petah Tikva, Israel, develops small molecules that act on the adenosine A3 receptor, which is overexpressed in tumour and inflamed cells. Namodenoson is in a phase 3 trial in hepatocellular carcinoma with Child-Pugh B liver function, a group with few options, and piclidenoson is tested in psoriasis. Its trials are registered on ClinicalTrials.gov under Can-Fite as lead sponsor.
Similar pages
- CompanyImmunitor
Shares Pivotal (registrational) trial, Clinical trial, Hepatocellular carcinoma.
- CompanyGC Cell
Shares Pivotal (registrational) trial, Clinical trial, Hepatocellular carcinoma.
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals